BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21701086)

  • 1. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
    Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
    Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
    Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
    Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
    Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
    Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
    Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
    Javadi J; Dobra K; Hjerpe A
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
    J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
    Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
    Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATG5 as biomarker for early detection of malignant mesothelioma.
    Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
    BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The established and future biomarkers of malignant pleural mesothelioma.
    Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
    Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.